Pasithea Therapeutics Revenue

Revenue (ttm)

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

Market Cap

17.18M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	-	-	-
Dec 31, 2024	-	-	-
Dec 31, 2023	-	-	-
Dec 31, 2022	-	-	-
Dec 31, 2021	15.06K	-	-
Dec 31, 2020	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

KTTA News

4 weeks ago - Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity - GlobeNewsWire
2 months ago - Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
3 months ago - Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - GlobeNewsWire
5 months ago - Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock - GlobeNewsWire
5 months ago - Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock - GlobeNewsWire
5 months ago - Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data - GlobeNewsWire
5 months ago - Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients - GlobeNewsWire
5 months ago - Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - GlobeNewsWire

More News